0000899243-22-028981.txt : 20220817 0000899243-22-028981.hdr.sgml : 20220817 20220817161713 ACCESSION NUMBER: 0000899243-22-028981 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220815 FILED AS OF DATE: 20220817 DATE AS OF CHANGE: 20220817 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mahmood Nadir CENTRAL INDEX KEY: 0001816598 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39370 FILM NUMBER: 221174239 MAIL ADDRESS: STREET 1: 6000 SHORELINE COURT STREET 2: SUITE 102 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nkarta, Inc. CENTRAL INDEX KEY: 0001787400 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474515206 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6000 SHORELINE COURT STREET 2: SUITE 102 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 415-582-4923 MAIL ADDRESS: STREET 1: 6000 SHORELINE COURT STREET 2: SUITE 102 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-08-15 0 0001787400 Nkarta, Inc. NKTX 0001816598 Mahmood Nadir C/O NKARTA, INC. 6000 SHORELINE COURT, SUITE 102 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 See Remarks Common Stock 2022-08-15 4 M 0 7500 3.89 A 53588 D Common Stock 2022-08-15 4 S 0 7500 18.0287 D 46088 D Stock Option (right to buy) 3.89 2022-08-15 4 M 0 4819 0.00 D 2029-09-05 Common Stock 4819 27703 D Stock Option (right to buy) 3.89 2022-08-15 4 M 0 2681 0.00 D 2029-09-05 Common Stock 2681 68062 D The transactions reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the trade date. This transaction was executed in multiple trades at prices ranging from $18.00 to $18.16. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. The options exercised were fully vested. Unvested options will vest and become exercisable ratably in monthly installments until fully vested on July 1, 2024. The options exercised were fully vested. Unvested options will vest and become exercisable ratably in monthly installments until fully vested on September 5, 2023. Chief Financial and Business Officer /s/ Alicia Hager, as Attorney-in-Fact 2022-08-17